NewAmsterdam Pharma Company NAMS Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's investing cash flow?
- NewAmsterdam Pharma Company (NAMS) reported investing cash flow of -$11.51M in Q1 2026.
- How has NewAmsterdam Pharma Company's investing cash flow changed year-over-year?
- NewAmsterdam Pharma Company's investing cash flow decreased by 503.1% year-over-year, from $2.86M to -$11.51M.
- What is the long-term trend for NewAmsterdam Pharma Company's investing cash flow?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's investing cash flow has grown at a 827.3% compound annual growth rate (CAGR), from -$24K to -$177.42M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.